Connect with us

News

Antibodies May Begin To Decline Six Weeks Following The Second Coronavirus Vaccination According To A New Study

According to studies, antibody levels created by two doses of the Oxford AstraZeneca or Pfizer BioNTech coronavirus vaccine may begin to decline six weeks after the second shot, and may drop by up to 50% in less than three months for some people.
Since antibodies are likely to decline, this means people will be less protected from the virus.
It’s also unclear how quickly concentrations can rise in the presence of infection, a phenomenon called as memory response.
But, in preparation of losing immunity, the NHS in England will begin planning a coronavirus booster jab program in September.
(PA Graphics) / PA Graphics While officials have stated that a third vaccine may not be required, scientific advisers to the government have stated that they are not taking any chances.
The Virus Watch study at UCL looked at blood from 552 persons who had been vaccinated, most of whom were in their 50s and 60s.
Antibody levels varied greatly among patients, but a double dose of Pfizer/BioNTech produced more antiviral antibodies than two Oxford shots.
Antibody levels in the Pfizer vaccine declined from an average of 3320 units per millilitre (ml) at 70 days to an average of 21-41 days.
They dropped from 1201 units per ml at 0-20 days to 190 units per ml at 70 or more days for the Oxford jab.
The findings were reported in a study letter to the Lancet journal.
“In the light of recent Joint Committee on Vaccination and Immunisation guidance in support of booster vaccines, and given the potentially rapid S-antibody decrease shown by these data, heterologous regimens, which preliminary data suggest elicit larger antibody and T-cell responses, might provide more permanent immunity and greater protection against emerging infections,” the scientists write.
“Principally, in the light of expanding global vaccination disparities, the ethical justification for universal booster dose deployment in high-income settings should be carefully reviewed,” they write.
“Data on inequalities in peak antibody levels and rates of decrease could thus influence targeted and equitable booster deployment,” said Eleanor Riley, professor of immunology and infectious disease at the University of Edinburgh.
“Antibody concentrations degrade at a predictable, exponential pace in the absence of continued antibody manufacture.”
This isn’t always a bad thing.
“The two most important characteristics are the lowest antibody concentration required for protection and how rapidly antibody concentrations can rise again in the face of infection (the so-called memory response).”
“This study does not answer these concerns, which are maybe the most important questions we need to answer in order to identify the need for booster doses,” she said. “mRNA vaccines, like the Pfizer/BioNtech vaccine, are designed to induce high quantities of antibodies.”
“Viral vectored vaccines (like the Oxford/AstraZeneca vaccine) tend to elicit lower antibody responses but higher T cell responses.”
As a result, the differences in antibody concentrations elicited by the two vaccines are neither surprising nor alarming.
“Yet, new research suggests that antibodies are especially critical for halting infection and preventing virus transmission, whereas T cells may be especially important for preventing severe disease and death.”

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Must See

More in News